课题基金 / 基金详情

Development of next generation drugs for chronic myeloid leukaemia

Development of next generation drugs for chronic myeloid leukaemia
开发下一代治疗慢性粒细胞白血病的药物
批准号：
nhmrc : 1060225
负责人：
Dr Quentin Kaas
金额：
$42.19万
依托单位：
The University of Queensland
依托单位国家：
澳大利亚
项目类别：
Project Grants
财政年份：
2014
资助国家：
澳大利亚
项目状态：
已结题
起止时间：
2014-01-01 至 2016-12-31
来源：
https://researchdata.edu.au/development-generation-drugs-myeloid-leukaemia/454810
关键词：
Developmentnextgenerationdrugschronic

项目摘要

项目成果

Dr Quentin Kaas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Chronic myeloid leukaemia (CML) is one of the four most common types of leukaemia. With current therapies, 15–20% of patients newly diagnosed for CML will die in the next five years, and it is therefore vitally important to discover new treatments. The aim of this project is to develop a new generation of drugs to treat CML based on new approaches (i.e., different type of molecules and different binding site) that can combat the resistance acquired to the current treatments.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Theoretical and computational approaches to accurately predict the structures of a unique family of circular and knotted proteins.
  • 批准号：
    DP0773830
  • 项目类别：
    Discovery Projects
  • 资助金额：
    $18.25万
  • 财政年份：
    2007
  • 负责人：
    Dr Quentin Kaas
  • 依托单位：
    The University of Queensland
国内基金
海外基金
Next Generation Majorana Nanowire Hybrids